Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

A women who weaned herself off Ozempic and has now quit using the drug has explained the effect it had on her body. GLP-1 ...

People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of ...

By Diana Novak Jones (Reuters) -A federal judge has rejected a bid by compounding pharmacies to allow them to continue making ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Among patients with moderate peripheral artery disease, GLP-1 use was associated with reduced risk for cardiovascular and ...